The newer progestogens gestodene, desogestrel and norgestimate were developed in an
attempt to produce agents with more selective progestational activity that would improve …

The aim of this study was to compare contraceptive reliability, cycle control, and tolerance of
an oral contraceptive containing 20 μg ethinylestradiol (EE2) and 75 μg gestodene (GSD) …

The clinical and metabolic effects of a low-dose triphasic oral contraceptive containing
gestodene were investigated in 42 healthy women during 6 months of treatment. No …

The effects of felbamate on the pharmacokinetics of a low‐dose combination oral
contraceptive containing 30 μg ethinyl estradiol and 75 μg gestodene were assessed in a …

Serum levels of 3-ketodesogestrel and ethinyl estradiol were analyzed by
radioimmunoassay in a balanced crossover study with two tablet formulations containing …

The aim of this study was to compare contraceptive reliability, cycle control and tolerance of
an oral contraceptive containing 20 μg ethinylestradiol and 75 μg gestodene, with a …

This clinical investigation of a low-dose, monophasic gestodene-containing oral
contraceptive (75 μg gestodene/30 μg ethinylestradiol), investigated contraceptive efficacy …

Ovulation inhibition by the monophasic oral contraceptive containing 75 μg of gestodene
and 30 wg of ethinyl estradiol was evaluated in 25 healthy volunteers for five cycles: a …

Two triphasic oral contraceptives containing the same amount of ethinyl estradiol in
combination with gestodene or levonorgestrel were compared with respect to contraceptive …

The metabolic effects of a new oral contraceptive Femodene (SHD 356C) containing 75 μg
gestodene (Δ-15-levonorgestrel) and 30 μg ethinyloestradiol were studied in two groups of …